The Institute of Biophysics and Cell Engineering offers consumers mesenchymal stem cells induced to differentiate in the osteogenic direction under a manufacturing agreement and is looking for partners to conclude a distribution services agreement.

The biomedical cell product is adult mesenchymal stem cells with confirmed differentiation in the osteogenic direction (hereinafter referred to as MSCOD). Along with the main therapeutic properties of multipotent mesenchymal stem cells, MSCs are able to initiate and maintain the process of local osteogenesis.

The optimal biomaterial for the isolation of native MSCs in an adult for the purpose of their further cultivation and subsequent targeted osteoinduction is adipose tissue. Due to the ability of MSCs to actively proliferate in vitro, it is always possible to obtain a cell dose sufficient for successful clinical use. To confirm the osteogenic differentiation of MSCs, the most reliable technology is used - real-time polymerase chain reaction (PCR).

One of the areas of application of MSCOD is traditionally considered to be dentistry, in particular, the treatment of periodontal diseases. Pathological changes in chronic periodontitis, leading to the destruction of the bone structures of the tooth socket, are a natural field of activity for regenerative technologies.

After local transplantation of MSCO on a collagen membrane into the periodontal pocket, the process of regeneration and formation of bone tissue begins. The activity of MSCOD ensures the launch of reparative osteohistogenesis. The angiogenic activity of MSCOD with the formation of a new microvasculature in healthy tissues surrounding the tooth stimulates the recruitment and proliferation of resident mesenchymal cells of the recipient bed.



Price list for biomedical cell products for foreign citizens (RU) can be downloaded here (in Russian).

The application of MSCO to biocompatible carrier materials, such as collagen, makes it possible to create simple tissue engineering constructs for effective reparative osteogenesis in vivo.

Directions of fundamental and applied scientific researches of researches of the Institute.

In the field of medical biotechnology:
- genetic engineering - development of innovative biomedical cell products based on genetically modified cells;
- immunology and allergology - development of new methods of treatment and diagnosis of allergic diseases and immune dysfunctions;
- innovative vaccines - development of prototypes of domestic DNA and RNA vaccines for the prevention of viral diseases;
- new approaches to diagnostics - development of new technologies for early diagnosis of diseases and methods of personalized medicine aimed at improving the quality of human life;
- genome editing - somatic, induced pluripotent stem cells, which will allow to treat diseases, including orphan, genetic ones;
- synthetic morphogenesis - including engineering of tissues and organs.

In the field of bioinformatics technologies:
- structurally based design of new generation drugs, development of innovative targeted anticancer and antiviral drugs using structural bioinformatics methods;
- synthesis of targeted drugs and their testing under in vitro conditions.

In the field of nanotheranostics and personalized nanomedicine:
- development of means of targeted delivery of therapeutic drugs of a new generation using nanomaterials;
- development of biological nanochips for the diagnosis of diseases;
- study of biocompatible nanomaterials with a wide spectrum of action for the creation of biomedical cellular products, artificial organs, fundamentally new materials with antimicrobial, antiviral and anti-inflammatory activity.

Activities of the Center for Experimental and Applied Virology:
- cultivation of viruses, development of new methods of cultivation of human viruses to create diagnostic tools, medical prevention and treatment of viral diseases;
- creation of prototype vaccines - against influenza (inactivated and recombinant), against African swine fever (vector), against pulmonary tuberculosis (therapeutic based on donor dendritic cells), innovative drugs against influenza.

Over the past years, the Institute has been fulfilling a number of international contracts and agreements within the Framework Programs of the European Union, as well as with leading scientific centers, foundations, and societies.

Consumers interested in purchasing mesenchymal stem cells induced to differentiate in the osteogenic direction under a manufacturing agreement.

Partners interested in purchasing mesenchymal stem cells induced to differentiate in the osteogenic direction under a distribution services agreement.